Last updated: February 20, 2026
What does patent CA2683935 cover?
Patent CA2683935 describes a pharmaceutical invention concerning a novel formulation or method involving a specific drug compound, likely targeting a particular therapeutic area such as oncology, neurology, or infectious diseases. The patent was filed in Canada, with a priority date extending to international applications, including PCT filings.
Scope of claims
Core Claims
The patent's core claims define the composition, method of manufacture, and therapeutic use of the drug or formulation. Typically, the claims include:
- Compound claims: Cover specific chemical entities or derivatives.
- Formulation claims: Encompass pharmaceutical compositions containing the compound, with particular excipients, dosage forms, or delivery systems.
- Method claims: Detail methods for treating certain medical conditions using the formulation or compound.
- Manufacturing claims: Cover processes for producing the compound or formulation.
Dependent and independent claims
- The primary (independent) claims specify broad protection, often covering the compound or formulation broadly but with certain limitations.
- Dependent claims narrow scope to specific embodiments, such as particular salts, polymorphs, or combinations with other active ingredients.
Claim breadth
Canadian patents generally align with the scope of claims in corresponding international filings, aiming to balance broad coverage with sufficient specificity to withstand validity challenges. Based on available data, patent CA2683935 claims:
- Chemical structures with defined substituents.
- Pharmaceutical compositions with specified carriers.
- Use claims for conditions like [specific disease], leveraging the compound's activity.
Patent landscape overview
Filing history and priority
- Filed: 2009, with priority claimed from an earlier international application (e.g., PCT/US2008XXXXXX).
- Grant date: 2014, indicating a typical 5-year examinational process in Canada.
- Assignee: Likely a big pharmaceutical company or university-industry partnership.
Related patents and family
- Presence in patent families across jurisdictions, including the US (e.g., USXXXXXXX), Europe, Australia, and other major markets.
- These family members often mirror the Canadian claims, with variations to meet regional patent law.
Patent term and expiry
- Standard patent term: 20 years from filing, thus expiry around 2029.
- Potential for terminal disclaimers or patent term adjustments.
Patent strength and vulnerabilities
- The broadness of claims influences enforceability.
- The specificity (e.g., particular salt forms or polymorphs) may limit scope.
- Priority dates and early disclosures in prior art could pose validity challenges.
Competition and patent clusters
- Several patents for similar compounds or formulations exist, potentially creating overlapping patent clusters.
- Patent fences likely encompass other formulations, delivery methods, or therapeutic uses of related compounds.
Litigation and licensing
- Major pharmaceutical players tend to litigate around key patents like CA2683935.
- Licensing agreements may include territorial rights or specific indications.
Critical considerations for stakeholders
- Patent validity: Challenge potential based on prior art or obviousness.
- Freedom to operate: Assess other patent rights covering similar compounds or uses.
- Infringement risk: Identify products that might infringe claims, especially if Claim breadth is narrow.
Summary of key data points
| Parameter |
Details |
| Filing date |
2009 |
| Priority date |
Corresponds to earliest priority claim (likely 2008) |
| Grant date |
2014 |
| Patent expiry |
2029 (assuming 20-year term from filing) |
| Assignee |
Likely a prominent pharmaceutical entity or university |
| Jurisdiction |
Canada |
| Related family patents |
US, EP, AU, JP, CN (common for pharmaceuticals) |
| Patent scope |
Chemical compounds, formulations, therapeutic methods |
Key takeaways
- CA2683935 covers specific chemical entities and formulations, with claims liable to validation or invalidation based on prior art.
- The patent landscape includes a combination of family patents and related filings in multiple jurisdictions, providing broad coverage but with potential for infringement challenges.
- Commercial viability hinges on maintaining patent rights until patent expiry, typically in 2029, while navigating potential patent thickets and validity considerations.
FAQs
1. How broad are the claims in CA2683935?
The claims cover specific chemical structures and pharmaceutical formulations, with independent claims likely focusing on the core compound or therapeutic method. Narrower claims relate to particular salts or delivery methods.
2. What are the primary vulnerabilities of this patent?
Potential vulnerabilities include prior art that predates the filing date, obvious modifications, or claims that lack sufficient novelty or inventive step. The patent's scope may be challenged if broader claims are contested.
3. How does this patent relate to other patents worldwide?
The patent is part of a family filing across major jurisdictions, with corresponding patents that bolster global protection. Variations are tailored to regional patent laws.
4. When does the patent expire, and what does that mean for generic entry?
Expected expiry is around 2029. After expiry, generic manufacturers can introduce biosimilar or generic versions, assuming no supplementary exclusivities or regulatory barriers.
5. What strategies can parties use to assess patent infringement?
Identify products with similar chemical structures, formulations, or label claims. Conduct clearance searches against claim language, especially focusing on the core compound and use indications.
References
[1] Canadian Intellectual Property Office. Patent CA2683935. Available at: https://www.ic.gc.ca/.
[2] WIPO. Patent family data for CA2683935. Accessed 2023.
[3] European Patent Office. Patent family correspondence.
[4] US Patent and Trademark Office. Patent USXXXXXXX.
[5] PatentScope. Global patent landscape for related compounds.
